<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03250728</url>
  </required_header>
  <id_info>
    <org_study_id>K170703J</org_study_id>
    <secondary_id>2017-A02141-52</secondary_id>
    <nct_id>NCT03250728</nct_id>
  </id_info>
  <brief_title>Role of the Endothelium in Stroke-like Episode Among CDG Patients</brief_title>
  <acronym>PECDG</acronym>
  <official_title>Role of the Endothelium in Stroke-like Episode Among CDG Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the role of the endothelial barrier in the occurrence of
      stroke-like episode. And to study the protein C system on the surface of the endothelium.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists in isolating endothelial progenitor cells in peripheral blood. After blood
      puncture, PBMC (peripheral blood mononuclear cell) are isolated by Ficoll gradient and then
      culturing in appropriated medium.

      When cells are confluent, investigators can study the endothelial barrier by using
      permeability assay and transendothelial resistance test (iCELLigence technology).

      Then, protein C system will be studied. Indeed, EPCR (Endothelial protein C receptor) and TM
      (thrombomodulin), are the two receptors responsible for the activation of protein C. The
      expression of these receptors will be assessed in flow cytometry. The activated protein C is
      able to interact with the third receptor PAR1 (Protease activated receptor 1) which is
      responsible for the protective effects of the on the endothelial barrier. The PAR1 expression
      will be studied in flow cytometry also.

      In order to measure the capacity of the protein C system to generate activated protein C
      investigators will assay an activated protein C generation on the cell surface.

      All these assays will be realized in basal condition and in heat stress (42°C), to mimic the
      stroke-like episode environment. Indeed, stroke-like episodes occur always during febrile
      illness.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 23, 2017</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial permeability assay in basal condition</measure>
    <time_frame>at inclusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Endothelial permeability assay after an heat shock</measure>
    <time_frame>at inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Activated protein C generation assay on the endothelial cell surface</measure>
    <time_frame>at inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of the endothelial receptors (EPCR, TM, PAR1)</measure>
    <time_frame>at inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial permeability assay after an activated protein C incubation</measure>
    <time_frame>at inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Congenital Disorders of Glycosylation</condition>
  <arm_group>
    <arm_group_label>CDG with stroke-like history</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CDG without stroke-like history</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peripheral blood puncture</intervention_name>
    <description>Endothelial progenitor cells will be isolated from peripheral blood by density gradient and cultured in 10%FBS EGM2 medium
On the EPCs we will study:
the endothelial permeability
the protein C system</description>
    <arm_group_label>CDG with stroke-like history</arm_group_label>
    <arm_group_label>CDG without stroke-like history</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with CDG molecularly diagnosed

          -  with stroke-like history or not

        Exclusion Criteria:

          -  rejection to participate in research
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascale De Lonlay, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Delphine Borgel, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pascale De Lonlay, MD, PhD</last_name>
    <phone>+33 1 42 19 26 94</phone>
    <email>pascale.delonlay@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nelly Briand, PhD</last_name>
    <phone>+33 1 44 38 18 62</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Necker enfants malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine Borgel, MD, PhD</last_name>
      <phone>+33 1 44 49 49 46</phone>
      <email>delphine.borgel@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Tiffany Pascreau, MD, PhD</last_name>
      <phone>+ 33 1 44 49 49 46</phone>
      <email>tiffany.pascreau@aphp.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2017</study_first_submitted>
  <study_first_submitted_qc>August 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2017</study_first_posted>
  <last_update_submitted>January 15, 2018</last_update_submitted>
  <last_update_submitted_qc>January 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CDG</keyword>
  <keyword>Stroke-like</keyword>
  <keyword>Endothelial progenitor cells (EPCs)</keyword>
  <keyword>Protein C</keyword>
  <keyword>Congenital Disorders og Glycosylation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Disorders of Glycosylation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

